Technology/ Title	**LDOC1 IHC-Based Patient Stratification for Predicting EGFR-TKI Treatment Benefit** (以 LDOC1 IHC 輔助 EGFR-TKI 療效預測與病患分層)	
Subtitle	**A pathology-compatible IVD opportunity to reduce EGFR-TKI trial-and-error costs** **(以既有病理流程導入的 IVD 商機，降低 EGFR-TKI 試錯成本)**	
Technology Type	□ Biotechnology	■Device/Diagnostics
Contact Person	Name: Chia-Huei Lee 李家惠	Title: Associate Investigator
	Telephone(work): +886-37206166-31740	Mobile:
	Email: chlee124@nhri.edu.tw	
Link	https://nicr.nhri.edu.tw/pi/leech_cv/	
Technology Description	LDOC1 IHC-based decision-support assay for predicting EGFR-TKI treatment benefit in EGFR-mutated NSCLC. The assay uses FFPE tumor tissue and a proprietary anti-LDOC1 mAb to classify patients into LDOC1-high or -low groups, with optional AI-assisted scoring.	
Intellectual Property	● Taiwan patent granted for LDOC1 IHC-based EGFR-TKI benefit prediction; U.S. patent pending. ● Anti-LDOC1 mAb provisional patent filed, with PCT planned.	
Key Publications	● Huang HN†, Hung PF, Tsai YT, Cha TL, Chen YP, Weng WT, Sun CY, Yu WH, Cheng HL and **Lee CH***†. LDOC1 connects histone H2B monoubiquitination to tumor cell plasticity in non-small cell lung cancer. *Cell Commun. and Signal.* 2026, 24(1):64. ● Huang HN†, Hung PF, Chen YP, and **Lee CH***†. Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer. ***Int. J. Mol. Sci.* 2024,** 25(3):1374.	
Business Opportunity	Seeking partners for clinical validation, IVD kit licensing, and co-development of an LDOC1 IHC-based EGFR-TKI benefit prediction assay. Potential applications include LDT/Central Lab testing, diagnostic company licensing, and pharma collaboration for trial stratification or CDx development.	